Authors

Latest:

Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer

Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.

Eduardo G. Moros, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Eduardo Sotomayor, MD

Latest:

Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment Arsenal

Eduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.

Eduardo Sotomayor, MD, GW Cancer Center

Edward A. Eikman, MD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Edward A. Levine, MD

Latest:

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis

The management of patients with malignant peritoneal surface disease (PSD) commonly known as "carcinomatosis" continues to evolve.

Edward A. Stadtmauer, MD

Latest:

Dr. Stadtmauer on the Evolving Treatment Landscape in Multiple Myeloma

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

Edward A. Stadtmauer, MD, University of Pennsylvania

Edward B. Garon, MD

Latest:

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Edward B. Garon, MD, David Geffen School of Medicine at UCLA

Edward B. Garon, MD, MS

Latest:

The Future of Tumor Agnostic Therapies in EGFRm m NSCLC

Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.

Edward Bradley, MD

Latest:

Dr. Bradley on OX40 for the Treatment of Cancer

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Edward Garon, MD

Latest:

Dr Garon on Considerations for Perioperative Immunotherapy Use in Lung Cancer

Edward B. Garon, MD, MS, discusses key considerations when selecting an optimal perioperative treatment approach for patients with lung cancer.

Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA

Latest:

Managing Toxicities in Short- and Long-Term Treatment with ADCs

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Edward Kim, MD, Levine Cancer Institute, Atrium Health

Edward Kim, MD, University of California Davis

Edward P. Ambinder, MD

Latest:

More Progress Needed to Bring Oncology Practice Into the Digital Health Age

Much needs to be done to improve interoperability of medical data systems. However, standards and new systems are developing at a rapid pace, affording advantages and efficiencies where, previously, enormous impediments stood in the way.

Edward S. Kim, MD

Latest:

Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Edward S. Kim, MD, FACP, Carolinas HealthCare System

Edward S. Kim, MD, Levine Cancer Institute